Having trouble accessing articles? Reset your cache.

CYT387: Phase I/II data

In the dose-escalation Phase I portion of a Phase I/II trial in 21 patients, 100, 150, 200, 300 and 400 mg daily CYT387

Read the full 231 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE